Zobrazeno 1 - 10 of 382 pro vyhledávání: '"Bassil, AK"'
1
Akademický článek
Phase 1 and preclinical profiling of ESM-HDAC391, a myeloid-targeted histone deacetylase inhibitor, shows enhanced pharmacology and monocytopaenia.
Autor: Furze RC; Research & Development, GlaxoSmithKline, Stevenage, Hertfordshire, UK., Molnar J; Research & Development, GlaxoSmithKline, Stevenage, Hertfordshire, UK.; Galapagos, Cambridge, UK., Parr NJ; Research & Development, GlaxoSmithKline, Stevenage, Hertfordshire, UK.; MoonFire Consultancy Ltd, Hertfordshire, UK., Ahmad F; Research & Development, GlaxoSmithKline, Stevenage, Hertfordshire, UK.; Galderma R&D, Fort Worth, TX, USA., Henry Y; Research & Development, GlaxoSmithKline, Stevenage, Hertfordshire, UK.; YMH-Management Ltd, Lancashire, UK., Howe D; Research & Development, GlaxoSmithKline, Stevenage, Hertfordshire, UK.; SoseiHeptares, Cambridge, UK., Singh R; Research & Development, GlaxoSmithKline, Stevenage, Hertfordshire, UK.; GlaxoSmithKline, Collegeville, PA, USA., Toal M; Research & Development, GlaxoSmithKline, Stevenage, Hertfordshire, UK.; Conan Biopharma Consulting, Wokingham, UK., Bassil AK; Research & Development, GlaxoSmithKline, Stevenage, Hertfordshire, UK., Bernard SG; Research & Development, GlaxoSmithKline, Stevenage, Hertfordshire, UK., Davis RP; Research & Development, GlaxoSmithKline, Stevenage, Hertfordshire, UK., Gibson A; Research & Development, GlaxoSmithKline, Stevenage, Hertfordshire, UK., Maller NC; Research & Development, GlaxoSmithKline, Stevenage, Hertfordshire, UK., Sharp C; Research & Development, GlaxoSmithKline, Stevenage, Hertfordshire, UK., Tough DF; Research & Development, GlaxoSmithKline, Stevenage, Hertfordshire, UK., Prinjha RK; Research & Development, GlaxoSmithKline, Stevenage, Hertfordshire, UK., Lewis HD; Research & Development, GlaxoSmithKline, Stevenage, Hertfordshire, UK.
Publikováno v: British journal of clinical pharmacology [Br J Clin Pharmacol] 2022 Dec; Vol. 88 (12), pp. 5238-5256. Date of Electronic Publication: 2022 Jul 11.
Zobrazit plný text záznamu
2
Akademický článek
Inhibition of colonic motility and defecation by RS-127445 suggests an involvement of the 5-HT2B receptor in rodent large bowel physiology.
Autor: Bassil, AK1, Taylor, CM2, Bolton, VJN1, Gray, KM1, Brown, JD2, Cutler, L1, Summerfield, SG3, Bruton, G1, Winchester, WJ1, Lee, K1, Sanger, GJ1, Bassil, A K4 (AUTHOR), Taylor, C M (AUTHOR), Bolton, V J N (AUTHOR), Gray, K M (AUTHOR), Brown, J D (AUTHOR), Summerfield, S G (AUTHOR), Winchester, W J (AUTHOR), Sanger, G J (AUTHOR)
Publikováno v: British Journal of Pharmacology. Sep2009, Vol. 158 Issue 1, p252-258. 7p.
Zobrazit plný text záznamu
3
Akademický článek
Docking‑based virtual screening of BRD4 (BD1) inhibitors: assessment of docking methods, scoring functions and in silico molecular properties.
Autor: Dong, Junmin1 (AUTHOR), Hao, Xiaohua1 (AUTHOR) hxh3949@bjsjth.cn
Publikováno v: BMC Chemistry. 12/18/2024, Vol. 18 Issue 1, p1-13. 13p.
Zobrazit plný text záznamu
4
Akademický článek
Selective targeting of BD1 and BD2 of the BET proteins in cancer and immunoinflammation.
Autor: Gilan O; Peter MacCallum Cancer Centre, Melbourne, VIC, Australia.; Sir Peter MacCallum Department of Oncology, University of Melbourne, Melbourne, VIC, Australia., Rioja I; Epigenetics RU, GlaxoSmithKline Medicines Research Centre, Stevenage, UK., Knezevic K; Peter MacCallum Cancer Centre, Melbourne, VIC, Australia., Bell MJ; Epigenetics RU, GlaxoSmithKline Medicines Research Centre, Stevenage, UK., Yeung MM; Peter MacCallum Cancer Centre, Melbourne, VIC, Australia., Harker NR; Epigenetics RU, GlaxoSmithKline Medicines Research Centre, Stevenage, UK., Lam EYN; Peter MacCallum Cancer Centre, Melbourne, VIC, Australia.; Sir Peter MacCallum Department of Oncology, University of Melbourne, Melbourne, VIC, Australia., Chung CW; Epigenetics RU, GlaxoSmithKline Medicines Research Centre, Stevenage, UK., Bamborough P; Epigenetics RU, GlaxoSmithKline Medicines Research Centre, Stevenage, UK., Petretich M; Cellzome GmbH, Functional Genomics R&D, GlaxoSmithKline, Heidelberg, Germany., Urh M; Promega Corporation, Madison, WI, USA., Atkinson SJ; Epigenetics RU, GlaxoSmithKline Medicines Research Centre, Stevenage, UK., Bassil AK; Epigenetics RU, GlaxoSmithKline Medicines Research Centre, Stevenage, UK., Roberts EJ; Epigenetics RU, GlaxoSmithKline Medicines Research Centre, Stevenage, UK., Vassiliadis D; Peter MacCallum Cancer Centre, Melbourne, VIC, Australia.; Sir Peter MacCallum Department of Oncology, University of Melbourne, Melbourne, VIC, Australia., Burr ML; Peter MacCallum Cancer Centre, Melbourne, VIC, Australia.; Sir Peter MacCallum Department of Oncology, University of Melbourne, Melbourne, VIC, Australia., Preston AGS; Epigenetics RU, GlaxoSmithKline Medicines Research Centre, Stevenage, UK., Wellaway C; Epigenetics RU, GlaxoSmithKline Medicines Research Centre, Stevenage, UK., Werner T; Cellzome GmbH, Functional Genomics R&D, GlaxoSmithKline, Heidelberg, Germany., Gray JR; Epigenetics RU, GlaxoSmithKline Medicines Research Centre, Stevenage, UK., Michon AM; Cellzome GmbH, Functional Genomics R&D, GlaxoSmithKline, Heidelberg, Germany., Gobbetti T; Epigenetics RU, GlaxoSmithKline Medicines Research Centre, Stevenage, UK., Kumar V; Computational Biology, GlaxoSmithKline, Collegeville, PA, USA., Soden PE; Epigenetics RU, GlaxoSmithKline Medicines Research Centre, Stevenage, UK., Haynes A; Epigenetics RU, GlaxoSmithKline Medicines Research Centre, Stevenage, UK., Vappiani J; Cellzome GmbH, Functional Genomics R&D, GlaxoSmithKline, Heidelberg, Germany., Tough DF; Epigenetics RU, GlaxoSmithKline Medicines Research Centre, Stevenage, UK., Taylor S; Epigenetics RU, GlaxoSmithKline Medicines Research Centre, Stevenage, UK., Dawson SJ; Peter MacCallum Cancer Centre, Melbourne, VIC, Australia.; Sir Peter MacCallum Department of Oncology, University of Melbourne, Melbourne, VIC, Australia.; Centre for Cancer Research, University of Melbourne, Melbourne, VIC, Australia., Bantscheff M; Cellzome GmbH, Functional Genomics R&D, GlaxoSmithKline, Heidelberg, Germany., Lindon M; Epigenetics RU, GlaxoSmithKline Medicines Research Centre, Stevenage, UK., Drewes G; Cellzome GmbH, Functional Genomics R&D, GlaxoSmithKline, Heidelberg, Germany., Demont EH; Epigenetics RU, GlaxoSmithKline Medicines Research Centre, Stevenage, UK., Daniels DL; Promega Corporation, Madison, WI, USA., Grandi P; Cellzome GmbH, Functional Genomics R&D, GlaxoSmithKline, Heidelberg, Germany., Prinjha RK; Epigenetics RU, GlaxoSmithKline Medicines Research Centre, Stevenage, UK. mark.dawson@petermac.org rabinder.prinjha@gsk.com., Dawson MA; Peter MacCallum Cancer Centre, Melbourne, VIC, Australia. mark.dawson@petermac.org rabinder.prinjha@gsk.com.; Sir Peter MacCallum Department of Oncology, University of Melbourne, Melbourne, VIC, Australia.; Centre for Cancer Research, University of Melbourne, Melbourne, VIC, Australia.
Publikováno v: Science (New York, N.Y.) [Science] 2020 Apr 24; Vol. 368 (6489), pp. 387-394. Date of Electronic Publication: 2020 Mar 19.
Zobrazit plný text záznamu
5
Akademický článek
Signaling function of PRC2 is essential for TCR-driven T cell responses.
Autor: Dobenecker MW; Laboratory of Immune Cell Epigenetics and Signaling, The Rockefeller University, New York, NY dobenem@rockefeller.edu., Park JS; Laboratory of Immune Cell Epigenetics and Signaling, The Rockefeller University, New York, NY., Marcello J; Laboratory of Immune Cell Epigenetics and Signaling, The Rockefeller University, New York, NY.; Now, Faculty of Biology, University of Freiburg, Freiburg, Germany., McCabe MT; Epigenetics Discovery Performance Unit, Oncology R&D, GlaxoSmithKline, Collegeville, PA., Gregory R; Epigenetics Discovery Performance Unit, Immuno-Inflammation TA, Medicines Research Centre, GlaxoSmithKline Research and Development, Stevenage, England, UK., Knight SD; Epigenetics Discovery Performance Unit, Oncology R&D, GlaxoSmithKline, Collegeville, PA., Rioja I; Epigenetics Discovery Performance Unit, Immuno-Inflammation TA, Medicines Research Centre, GlaxoSmithKline Research and Development, Stevenage, England, UK., Bassil AK; Epigenetics Discovery Performance Unit, Immuno-Inflammation TA, Medicines Research Centre, GlaxoSmithKline Research and Development, Stevenage, England, UK., Prinjha RK; Epigenetics Discovery Performance Unit, Immuno-Inflammation TA, Medicines Research Centre, GlaxoSmithKline Research and Development, Stevenage, England, UK., Tarakhovsky A; Laboratory of Immune Cell Epigenetics and Signaling, The Rockefeller University, New York, NY tarakho@rockefeller.edu.
Publikováno v: The Journal of experimental medicine [J Exp Med] 2018 Apr 02; Vol. 215 (4), pp. 1101-1113. Date of Electronic Publication: 2018 Mar 09.
Zobrazit plný text záznamu
6
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
7
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
8
Akademický článek
Potent antimyeloma activity of the novel bromodomain inhibitors I-BET151 and I-BET762.
Autor: Chaidos A; Centre for Haematology, Department of Medicine, Hammersmith Hospital, Imperial College London, London, United Kingdom;, Caputo V, Gouvedenou K, Liu B, Marigo I, Chaudhry MS, Rotolo A, Tough DF, Smithers NN, Bassil AK, Chapman TD, Harker NR, Barbash O, Tummino P, Al-Mahdi N, Haynes AC, Cutler L, Le B, Rahemtulla A, Roberts I, Kleijnen M, Witherington JJ, Parr NJ, Prinjha RK, Karadimitris A
Publikováno v: Blood [Blood] 2014 Jan 30; Vol. 123 (5), pp. 697-705. Date of Electronic Publication: 2013 Dec 13.
Zobrazit plný text záznamu
9
Akademický článek
Resistant starches from dietary pulses modulate the gut metabolome in association with microbiome in a humanized murine model of ageing.
Autor: Kadyan, Saurabh1 (AUTHOR), Park, Gwoncheol1 (AUTHOR), Wang, Bo2 (AUTHOR), Singh, Prashant1 (AUTHOR), Arjmandi, Bahram1 (AUTHOR), Nagpal, Ravinder1 (AUTHOR) rnagpal@fsu.edu
Publikováno v: Scientific Reports. 6/29/2023, Vol. 13 Issue 1, p1-14. 14p.
Zobrazit plný text záznamu
10
Akademický článek
The ghrelin agonist, HM01 activates central vagal and enteric cholinergic neurons and reverses gastric inflammatory and ileus responses in rats.
Autor: Yuan, Pu‐Qing1,2 (AUTHOR) pqyuan@mednet.ucla.edu, Wu, S. Vincent1 (AUTHOR), Wang, Lixin1,2 (AUTHOR), Taché, Yvette1,2 (AUTHOR)
Publikováno v: Neurogastroenterology & Motility. May2023, Vol. 35 Issue 5, p1-13. 13p.
Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání

Omezení vyhledávání
Plný text Recenzováno Digitální knihovna AV ČR
Zdroje